Výsledky vyhledávání

Akademický článek

PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis

Autor: Wenshu Li, Lichaoyue Sun, Sichao Yan

Publikováno v: Frontiers in Cardiovascular Medicine, Vol 11 (2024)

BackgroundAtherosclerotic cardiovascular disease (ASCVD), a leading cause of global fatalities, has inconsistent findings regarding the impact of muscle symptoms despite promising clinical trials involving PCSK9 inhibitors (PCSK9i) and siRNA as poten

Externí odkaz: https://doaj.org/article/d72a24554a4145ef8bfa9504415cff91

Zobrazit plný text záznamu

Akademický článek

PCSK9 monoclonal antibodies: An overview

Autor: Rasha Kaddoura, Bassant Orabi, Amar M Salam

Publikováno v: Heart Views, Vol 21, Iss 2, Pp 97-103 (2020)

PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-

Externí odkaz: https://doaj.org/article/1143e04c6e5843fc91b4a6276c34474e

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials

Autor: Xuan Li, Zhengzhong Wang, Qingjiao Sun, Qiang Geng

Publikováno v: Cardiology Journal. 29:574-581

Background: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bocociz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a824d02ecc44635fe4a2343b6453716c
https://doi.org/10.5603/cj.a2021.0110

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials

Autor: Alvaro Vicedo, Alberto Cordero, Alfonso Valle, Moisés Rodríguez-Mañero, José Ramón González-Juanatey, Jose Mª Castellano, José Seijas-Amigo, Manuel J Gómez-Martínez, Miriam Martín Toro, M Rosa Fernández-Olmo, Lorenzo Fácila

Publikováno v: J Diabetes Metab Disord

PURPOSE: Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors treatment induce large reductions in low-density lipoprotein cholesterol (LDLc) and major cardiovascular events. Clinical trials might have been underpowered to test the effect of P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab1291ea69d40c7f9c69df022a01f8f
https://doi.org/10.1007/s40200-020-00557-6

Zobrazit plný text záznamu

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update

Autor: Bassant Orabi, Amar M Salam, Rasha Kaddoura

Publikováno v: Journal of Drug Assessment
article-version (VoR) Version of Record

Objective Treatment of dyslipidemia lowers cardiovascular (CV) risk. Although statin use is a cornerstone therapy, many patients are not achieving their risk-specific low-density lipoprotein cholesterol (LDL-C) goals. The proprotein convertase subtil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b68536da2eb1b85352682d486690b0dc
https://pubmed.ncbi.nlm.nih.gov/32939318

Zobrazit plný text záznamu

Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Autor: Guodong Wu, Rui Liu, Chuang Li, Mei Zhang, Xueting Qin, Qi-Wen Chen

Publikováno v: American Journal of Cardiovascular Drugs. 20:343-353

Evidence shows a positive association between the use of statins and new-onset diabetes. There is, however, contradictory evidence as to whether a similar association exists for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::155676b709527b35cab485aab7a5441d
https://doi.org/10.1007/s40256-019-00386-w

Zobrazit plný text záznamu

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

Autor: Jack F. Bukowski, Paul M. Ridker, Daniel Baltrukonis, Pamela F. Schwartz, Ellen Q. Wang, Carla Yunis, Charles L. Shear

Publikováno v: Biodrugs

Background Anti-drug antibodies (ADAs) to bococizumab were detected in > 40% of subjects in the SPIRE lipid-lowering trials. The risk of cross-reactivity between anti-bococizumab antibodies and other approved anti-proprotein convertase subtilisin/kex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d070683c42e383e9b93e29732618fe6
https://doi.org/10.1007/s40259-019-00375-0

Zobrazit plný text záznamu

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease

Autor: Mohammad Alkhalil

Publikováno v: Current Drug Metabolism. 20:72-82

Background: Statins have been a major keystone in the management of patients with atherosclerotic cardiovascular disease. The benefits of inhibiting HMG CoA reductase, via statins, were translated into reduction in LDL-c with proportionate decrease i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fa662e00226979bcde67fa9f95a27e6
https://doi.org/10.2174/1389200219666180816141827

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání